APO-go

APO-go

apomorphine

Manufacturer:

Stada

Distributor:

HK Medical Supplies
/
Health Express
Concise Prescribing Info
Contents
Apomorphine HCl
Indications/Uses
Treatment of motor fluctuations ('on-off' phenomena) in patients w/ Parkinson's disease which are not sufficiently controlled by oral anti-Parkinson medication.
Dosage/Direction for Use
Individualised dosage. Patient will usually need to start domperidone at least 2 days prior to initiation of therapy. Pre-filled syringe Usual range: 3-30 mg/day as continuous SC infusion. Max: 100 mg/day. Pre-filled pen Usual range: 3-30 mg/day as intermittent SC bolus inj, given as 1-10 inj & sometimes 12 separate inj/day. Max: 100 mg/day. Individual bolus inj should not exceed 10 mg.
Contraindications
Hypersensitivity. Patients w/ resp depression, dementia, psychotic diseases, hepatic insufficiency. Must not be administered to patients w/ 'on' response to levodopa marred by severe dyskinesia or dystonia. Pregnancy & lactation. Childn & adolescent <18 yr.
Special Precautions
Use w/ caution in patients w/ renal, pulmonary or CV disease; patients prone to nausea & vomiting; patients taking vasoactive medicinal products eg, antihypertensives; patients w/ pre-existing postural hypotension; patients at risk for Torsades de pointes arrhythmia. Risk of local SC effects; haemolytic anaemia & thrombocytopenia; somnolence & episodes of sudden sleep onset; development of impulse control disorders; dopamine dysregulation syndrome. Neuropsychiatric disturbances may be exacerbated. Concomitant use w/ other medicinal products especially those w/ narrow therapeutic range. Minor or moderate influence on the ability to drive & use machines. Elderly &/or debilitated patients. Pre-filled syringe: Contains Na metabisulphite. Pre-filled pen: Contains Na bisulphite.
Adverse Reactions
Inj site & local reactions; hallucinations. Neuropsychiatric disturbances; transient sedation, somnolence, dizziness/light-headedness; yawning; nausea & vomiting.
Drug Interactions
Monitor for unusual side effects or signs of potentiation of effect when concomitantly administered w/ medications for Parkinson's disease. Antagonised effect w/ neuroleptic medicinal products eg, clozapine. May potentiate effect of antihypertensives. Avoid co-administration w/ other drugs known to prolong QT interval. Exercise caution when combining w/ other drugs, especially those w/ narrow therapeutic range.
MIMS Class
Antiparkinsonian Drugs
ATC Classification
N04BC07 - apomorphine ; Belongs to the class of dopamine agonist. Used in the management of Parkinson's disease.
Presentation/Packing
Form
APO-go infusion 5 mg/mL
Packing/Price
10 mL x 5 × 1's
Form
APO-go soln for inj 10 mg/mL
Packing/Price
3 mL x 5 × 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in